Phoenix Rising: The Gift That Keeps on Giving All Year Long
This holiday season Jody Smith turns her eyes to the people of Phoenix Rising and gives thanks for you all ...
Discuss the article on the Forums.

anbesol or benzocaine products caution

Discussion in 'Other Health News and Research' started by xrayspex, Jan 27, 2017.

  1. xrayspex

    xrayspex Senior Member

    I was going to use some anbesol over the counter product for sore teeth and saw a warning insert when opened the package--apparently it can cause in rare cases a condition called methemoglobinemia which sounds like a playbook for CFS.

    I read they didn't warn people right away but have finally started to provide cautionary info

    Reading about methemoglobinemia at wikipedia really made me wonder again about the role of anesthesia in the development of my CFS (had a surgery before).My white blood cells and some other bloodwork was way off post-surgery and wondering if could have been acute pyruvate kinase deficiency caused by the anesthesia. My finger turned blue another time when I had oral surgery with anesthesia for extraction a couple years ago-wonder if that was cyanosis. I regretted agreeing to the twilight anesthesia.

    Be careful of o-t-c products with anesthetics

    Methemoglobin is a form of hemoglobin that contains ferric [Fe3+] and ferrous [Fe2+] forms of iron. The affinity for oxygen of ferric iron is impaired. However, the ferrous iron in methemoglobin has an increased affinity for bound oxygen.[1] The binding of oxygen to methemoglobin results in an increased affinity for oxygen in the remaining heme sites that are in ferrous state within the same tetrameric hemoglobin unit.[2] This leads to an overall reduced ability of the red blood cell to release oxygen to tissues, with the associated oxygen–hemoglobin dissociation curve therefore shifted to the left. When methemoglobin concentration is elevated in red blood cells, tissue hypoxia may occur.

    Signs and symptoms[edit]
    Signs and symptoms of methemoglobinemia (methemoglobin level above 1%) include shortness of breath, cyanosis, mental status changes (~50%), headache, fatigue, exercise intolerance, dizziness and loss of hairlines.

    Patients with severe methemoglobinemia (methemoglobin level above 50%) may exhibit seizures, coma and death (>70%).[3] Healthy people may not have many symptoms with methemoglobin levels below 15%. However, patients with co-morbidities such as anemia, cardiovascular disease, lung disease, sepsis, or presence of other abnormal hemoglobin species (e.g. carboxyhemoglobin, sulfhemoglobin or sickle hemoglobin) may experience moderate to severe symptoms at much lower levels (as low as 5–8%).

    Normally, methemoglobin levels are <1%, as measured by the co-oximetry test. Elevated levels of methemoglobin in the blood are caused when the mechanisms that defend against oxidative stress within the red blood cell are overwhelmed and the oxygen carrying ferrous ion (Fe2+) of the heme group of the hemoglobin molecule is oxidized to the ferric state (Fe3+). This converts hemoglobin to methemoglobin, resulting in a reduced ability to release oxygen to tissues and thereby hypoxia. This can give the blood a bluish or chocolate-brown color.

    Spontaneously formed methemoglobin is normally reduced (regenerating normal hemoglobin) by protective enzyme systems, e.g., NADH methemoglobin reductase (cytochrome-b5 reductase) (major pathway), NADPH methemoglobin reductase (minor pathway) and to a lesser extent the ascorbic acid and glutathione enzyme systems. Disruptions with these enzyme systems lead to methemoglobinemia.

    Hypoxia occurs due to the decreased oxygen-binding capacity of methemoglobin, as well as the increased oxygen-binding affinity of other subunits in the same hemoglobin molecule, which prevents them from releasing oxygen at normal tissue oxygen levels.

    Arterial blood with elevated methemoglobin levels has a characteristic chocolate-brown color as compared to normal bright red oxygen-containing arterial blood.[3] If methemoglobinemia is suspected, an arterial blood gas and co-oximetry panel should be obtained.

    Methemoglobinemia may be acquired.[4] Classical drug causes of methemoglobinaemia include antibiotics (trimethoprim, sulfonamides, and dapsone[5]), local anesthetics (especially articaine, benzocaine, and prilocaine[6]), and aniline dyes, metoclopramide, rasburicase, chlorates, and bromates. Ingestion of compounds containing nitrates (such as the patina chemical bismuth nitrate) can also cause methemoglobinemia.

    In otherwise healthy individuals, the protective enzyme systems normally present in red blood cells rapidly reduce the methemoglobin back to hemoglobin and hence maintain methemoglobin levels at less than one percent of the total hemoglobin concentration. Exposure to exogenous oxidizing drugs and their metabolites (such as benzocaine, dapsone, and nitrates) may lead to an increase of up to a thousandfold of the methemoglobin formation rate, overwhelming the protective enzyme systems and acutely increasing methemoglobin levels.

    Infants under 6 months of age have lower levels of a key methemoglobin reduction enzyme (NADH-cytochrome b5 reductase) in their red blood cells. This results in a major risk of methemoglobinemia caused by nitrates ingested in drinking water,[7] dehydration (usually caused by gastroenteritis with diarrhea), sepsis, or topical anesthetics containing benzocaine or prilocaine. Nitrates used in agricultural fertilizers may leak into the ground and may contaminate well water. The current EPA standard of 10 ppm nitrate-nitrogen for drinking water is specifically set to protect infants.[7] Benzocaine applied to the gums or throat (as commonly used in baby teething gels, or sore throat lozenges) can cause methemoglobinemia.[8]

    The congenital form of methemoglobinemia has an autosomal recessive pattern of inheritance
    Due to a deficiency of the enzyme diaphorase I (NADH-cytochrome b5 reductase), methemoglobin levels rise and the blood of met-Hb patients has reduced oxygen-carrying capacity. Instead of being red in color, the arterial blood of met-Hb patients is brown. This results in the skin of Caucasian patients gaining a bluish hue. Hereditary met-Hb is caused by a recessive gene. If only one parent has this gene, offspring will have normal-hued skin, but if both parents carry the gene, there is a chance the offspring will have blue-hued skin.

    Another cause of congenital methemoglobinemia is seen in patients with abnormal hemoglobin variants such as hemoglobin M (HbM), or hemoglobin H (HbH), which are not amenable to reduction despite intact enzyme systems.

    Methemoglobinemia can also arise in patients with pyruvate kinase deficiency due to impaired production of NADH – the essential cofactor for diaphorase I. Similarly, patients with glucose-6-phosphate dehydrogenase deficiency may have impaired production of another co-factor, NADPH.

    Methemoglobinemia can be treated with supplemental oxygen and methylene blue[9] 1% solution (10 mg/ml) 1 to 2 mg/kg administered intravenously slowly over five minutes. Although the response is usually rapid, the dose may be repeated in one hour if the level of methemoglobin is still high one hour after the initial infusion. Methylene Blue inhibits monoamine oxidase and serotonin toxicity can occur if taken with an SSRI (selective serotonin reuptake inhibitor) medicine.[10]

    Methylene blue restores the iron in hemoglobin to its normal (reduced) oxygen-carrying state. This is achieved by providing an artificial electron acceptor (such as methylene blue or flavin) for NADPH methemoglobin reductase (RBCs usually don't have one; the presence of methylene blue allows the enzyme to function at 5× normal levels[11]). The NADPH is generated via the hexose monophosphate shunt.

    Genetically induced chronic low-level methemoglobinemia may be treated with oral methylene blue daily. Also, vitamin C can occasionally reduce cyanosis associated with chronic methemoglobinemia but has no role in treatment of acute acquired methemoglobinemia. Diaphorase It normally contributes only a small percentage of the red blood cell's reducing capacity, but can be pharmacologically activated by exogenous cofactors (such as methylene blue) to 5 times its normal level of activity.

    Last edited: Jan 27, 2017
  2. valentinelynx

    valentinelynx Senior Member

    Did you show desaturation (low oxygen saturation) during your anesthetic for extraction? The classic case of methemoglobinemia shows an O2 sat of 85% on the monitor. You have to have a pretty big exposure to benzocaine to get methemoglobinemia. It's not typically used as an injectable anesthetic, rather as a spray, or a topical like abnesol. So long as you are not coating your whole mouth with it, you should be OK.
    xrayspex likes this.

See more popular forum discussions.

Share This Page